Project description
New biomarker for Crohn’s disease early diagnosis
Chronic inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, type 1 diabetes, and Crohn's disease (CD) are becoming increasingly common and significantly impact quality of life. New blood markers allow for early diagnosis before symptoms appear, enabling timely and effective treatment. CD primarily affects young adults and can lead to complications such as painful fistulas and nutritional deficiencies, with biomarkers detectable up to seven years before diagnosis. The EU-funded INTERCEPT project will validate specific biomarkers in North American and European cohorts using stored serum samples. By developing a ‘serum signature’ and analysing it with an algorithm, the project will test this signature in 10 000 first-degree relatives of European CD patients across seven countries, demonstrating that early biomarker identification can help prevent CD symptoms.
Objective
Chronic inflammatory diseases such rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (t1D) and Crohn’s disease (CD) are increasingly common and cause important loss of quality of life and work productivity. Most of these conditions are diagnosed at a late stage of the disease; many patients have complications at diagnosis. For many of these conditions there are now methods or markers in the blood that allow diagnosis in the preclinical phase, meaning that individuals can be identified that have the disease but not yet the symptoms. This would allow very early treatment (which is highly effective) that prevents development of complications, which has been done successfully in RA, MS and t1D. CD mainly affects adolescents/young adults in the most productive phase of life. At diagnosis the majority of patients has fistulas (painful holes around the anus), stenosis of the bowel leading to crampy pain and metabolic symptoms such as weight loss, iron deficiency and other nutritional deficiencies. In CD, a number of molecules (‘markers’) have been identified in the blood of individuals up to 7 years before diagnosis. In the current project we wish to verify these markers in North American and European cohorts of which we have the serum available in freezers with the help of advanced laboratory tests leading to a ‘serum signature’. An algorithm will incorporate the relative importance of the different proteins to make it ready for widespread use. Then, we will test this signature in 10000 first degree relatives of European patients with CD across 7 countries, a process that is named ‘prospective validation’. In a final step we will demonstrate that if individuals are identified with the biomarker, CD symptom development can be halted (‘intercepted’) with medical treatment. If we succeed in this scientific work, the impact for the community would be enormous. We would be able to prevent suffering, surgeries, disability and loss of productivity significantly.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciencesclinical medicinerheumatology
- medical and health sciencesclinical medicinesurgery
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesclinical medicineendocrinologydiabetes
- social scienceseconomics and businesseconomicsproduction economicsproductivity
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Call for proposal
(opens in new window) HORIZON-JU-IHI-2024-07-single-stage
See other projects for this callFunding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
1081 HV Amsterdam
Netherlands
See on map
Participants (24)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1105 AZ AMSTERDAM
See on map
1070 313 Lisboa
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
1500-650 Lisboa
See on map
70182 Orebro
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
701 16 Orebro
See on map
10029 6574 New York
See on map
9220 Aalborg
See on map
00168 Roma
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
ROMA
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1080 VIENNA
See on map
1081 HV Amsterdam
See on map
02-507 WARSZAWA
See on map
1000 Bruxelles / Brussel
See on map
48011 BILBAO
See on map
9713 GZ Groningen
See on map
59037 Lille
See on map
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
7491 Trondheim
See on map
OX1 2JD Oxford
See on map
OX14 3EB Abingdon
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
8152 Glattpark
See on map
22014 Incheon
See on map
92121 SAN DIEGO
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.